SCHEMBL8512271

SCHEMBL8512271

O=C(NC(C(=O)OC1CN2CCC1CC2)c1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.55
▸ CHRM3 P20309 4/20 0.54
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ CYP2D6 P10635 1/20 0.52
▸ TSHR P16473 2/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ CHRM2 P08172 2/20 0.49
▸ CHRM1 P11229 2/20 0.49
▸ CHRNA7 P36544 3/20 0.49
▸ HTR3E A5X5Y0 1/20 0.49
▸ HTR3B O95264 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ HTR3A P46098 1/20 0.49
▸ HTR3D Q70Z44 1/20 0.49
▸ HTR3C Q8WXA8 1/20 0.49
▸ BCHE P06276 1/20 0.49
▸ ACHE P22303 1/20 0.49
▸ GAA P10253 1/20 0.47
▸ ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8512267 1.00 GLA (0.55) GLACHRM3NPC1RAB9ACYP2D6
SCHEMBL8509480 0.92 CHRM3 (0.62) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL8509482 0.92 CHRM3 (0.62) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL8510128 0.90 CHRM3 (0.54) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL8510121 0.90 CHRM3 (0.54) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL8511361 0.88 CHRM3 (0.52) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL8511357 0.88 CHRM3 (0.52) CHRM3CYP2D6CHRM2CHRM1CHRNA7
SCHEMBL13241021 0.86 NPC1 (0.56) GLACHRM3NPC1RAB9ACYP2D6
SCHEMBL19894968 0.84 CHRM3 (0.56) CHRM3CYP2D6TSHRRXFP1CHRM2
SCHEMBL1696012 0.84 NPC1 (0.59) GLACHRM3NPC1RAB9ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643295-B1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMA SPA (IT) 2016-04-13 — — EP disclosed
US-8772314-B2 Glycine derivatives and medicinal compositions thereof CHIESI FARMACEUTICI S.P.A. (IT) 2014-07-08 — — US disclosed
EP-2643295-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS Chiesi Farmaceutici S.p.A. (IT) 2013-10-02 — — EP disclosed
WO-2012069275-A1 GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 — — WO disclosed
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHIESI FARMACEUTICI S.P.A. (IT) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134934-A1 GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF CHRM3, GLRB, CHRNG GLA 942/4885CHRM3 1/4885NPC1 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback